Last $15.60 USD
Change Today -0.395 / -2.47%
Volume 6.4M
ACHN On Other Exchanges
As of 5:20 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

achillion pharmaceuticals (ACHN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $16.87
52 Week Low
05/7/14 - $2.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

achillion pharmaceuticals (ACHN) Related Businessweek News

No Related Businessweek News Found

achillion pharmaceuticals (ACHN) Details

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

61 Employees
Last Reported Date: 03/7/14
Founded in 1998

achillion pharmaceuticals (ACHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $326.4K
Chief Compliance Officer and Executive Vice P...
Total Annual Compensation: $334.4K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $313.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $256.7K
Compensation as of Fiscal Year 2013.

achillion pharmaceuticals (ACHN) Key Developments

Achillion Pharmaceuticals, Inc. Announces Results from Two Ongoing Clinical Trials

Achillion Pharmaceuticals, Inc. announced results from two ongoing clinical trials. In a six-week trial consisting of ACH-3102, a second generation NS5A inhibitor, and sofosbuvir in treatment-na ve genotype 1 HCV-infected patients, the Company reported 100% sustained viral response after four weeks of cessation of dosing, or SVR4. This study is an interferon-free, ribavirin-free, Phase 2 open-label, randomized study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, once daily, in treatment-na ve genotype 1 HCV-infected patients. The primary objective of the study is determination of sustained viral response 12 weeks after completion of therapy, or SVR12. The company also announced interim study results demonstrating that ACH-3422 achieved proof-of-concept in a Phase 1 trial for patients with treatment-na ve genotype 1 HCV. In the 700 mg dose group, mean maximal reduction in HCV viral RNA load of 4.8 log IU/ml was observed within 14 days with 3 out of 6 patients achieving undetectable HCV RNA (<10 IU/mL, target not detected). The pharmacodynamic characteristics of ACH-3422 provided sustained antiviral activity resulting in an additional 1.4 log reduction in HCV RNA between day 7 and day 14 of dosing.

Achillion Pharmaceuticals, Inc. - Special Call

To discuss positive interim results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422

Achillion Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Achillion Pharmaceuticals, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACHN:US $15.60 USD -0.395

ACHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACHN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACHILLION PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at